LIVTENCITY
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $585,157 | 1,190 | 761 |
| 2023 | $909,917 | 1,893 | 897 |
| 2022 | $303,355 | 1,129 | 735 |
| 2021 | $2,809 | 88 | 81 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $889,961 | 220 | 49.4% |
| Unspecified | $502,713 | 5 | 27.9% |
| Travel and Lodging | $168,448 | 595 | 9.4% |
| Food and Beverage | $150,214 | 3,458 | 8.3% |
| Space rental or facility fees (teaching hospital only) | $45,500 | 13 | 2.5% |
| Consulting Fee | $44,401 | 9 | 2.5% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RANDOMIZED CONTROLLED TRIAL COMPARING THE TOLERABILITY AND EFFICACY OF MARIBAVIR VS. VALGANCICLOVIR FOR CMV PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $196,050 | 0 |
| Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients | Takeda Pharmaceuticals U.S.A., Inc. | $170,851 | 0 |
| In vitro activity of approved and novel antiviral agents against Porcine CMV (PCMV) and Baboon CMV (BCMV) | Takeda Pharmaceuticals U.S.A., Inc. | $135,813 | 0 |
Top Doctors Receiving Payments for LIVTENCITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Kermaan Mehta | — | Bayville, NY | $548,893 | 26 |
| , M.D | Nephrology | Los Angeles, CA | $172,149 | 208 |
| , MD | Infectious Disease | Fort Worth, TX | $137,213 | 162 |
| , M.D., M.P.H | Nephrology | Fort Worth, TX | $105,286 | 135 |
| , D.O | Infectious Disease | Altamonte Springs, FL | $104,233 | 130 |
| , MD | Internal Medicine | Duarte, CA | $76,830 | 66 |
| , MD | Hematology | Chicago, IL | $65,421 | 35 |
| , M.D | Hematology & Oncology | Milwaukee, WI | $55,906 | 62 |
| , MD | Transplant Surgery | Los Angeles, CA | $54,723 | 56 |
| , MD | Infectious Disease | Altamonte Springs, FL | $46,570 | 52 |
| , M.D | Transplant Surgery | Houston, TX | $43,987 | 29 |
| , MD, PHD | Internal Medicine | Los Angeles, CA | $41,267 | 37 |
| , MD | Critical Care Medicine | Phoenix, AZ | $38,865 | 32 |
| Josh Levitsky | — | Chicago, IL | $38,292 | 38 |
| , M.D | Infectious Disease | Houston, TX | $33,763 | 11 |
| , MD | Nephrology | Denver, CO | $29,453 | 28 |
| , MD | Infectious Disease | Seattle, WA | $19,468 | 4 |
| , MD | Hepatology | New York, NY | $19,387 | 14 |
| , M.D | Pediatric Nephrology | West Hollywood, CA | $13,850 | 13 |
| , M.D | Transplant Surgery | Washington, DC | $13,592 | 13 |
| , MD | Hospitalist | Maywood, IL | $5,228 | 6 |
| , M.D | Internal Medicine | New York, NY | $4,965 | 2 |
| , MD | Internal Medicine | Boston, MA | $1,631 | 1 |
| , M.D | Nephrology | Phoenix, AZ | $506.80 | 27 |
| , MD | Nephrology | Loma Linda, CA | $475.67 | 14 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 1,946
- Transactions 4,300
About LIVTENCITY
LIVTENCITY is a drug associated with $1.8M in payments to 1,946 healthcare providers, recorded across 4,300 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2021 to 2024. In 2024, $585,157 was paid across 1,190 transactions to 761 doctors.
The most common payment nature for LIVTENCITY is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($889,961, 49.4% of total).
LIVTENCITY is associated with 3 research studies, including "RANDOMIZED CONTROLLED TRIAL COMPARING THE TOLERABILITY AND EFFICACY OF MARIBAVIR VS. VALGANCICLOVIR FOR CMV PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS" ($196,050).